Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly (MW ~4233.7 g/mol). It is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors, aiming to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-mediated increases in energy expenditure and hepatic fat reduction. Mazdutide was approved in China in June 2024 for chronic weight management, making it the first dual GLP-1/glucagon agonist to receive regulatory approval anywhere in the world. Phase III trials are ongoing in China for type 2 diabetes.
4 independent Janoshik purity tests cover Mazdutide across 4 vendors. Results range from 99.2% to 99.8%.
Category: Metabolic / Dual GLP-1/Glucagon Agonist. Evidence rating: C (early/mixed human evidence).
Clinical status: Approved in China (June 2024) for chronic weight management. Phase III in China for T2D. Not yet approved outside China.
Mazdutide is a fatty acid-acylated peptide that activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 receptor agonism provides glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite reduction — the same mechanisms as other GLP-1 agonists.…
Research base: 0 registered clinical trials and 5 indexed publications reference Mazdutide.
Safety considerations: Common: GI side effects including nausea, vomiting, diarrhea (similar to GLP-1 agonist class); GI adverse events are dose-dependent and generally transient; Heart rate increase observed, consistent with GLP-1 agonist class effect.
Reviewed by the PeptideAtlas Editorial Team.
| Molecular weight | ~4233.7 g/mol |
|---|---|
| Half-life | Suitable for once-weekly dosing (exact value not fully published) |
| Production method | recombinant |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Not currently in US clinical trials. Development focused on China. |
| Vendor | Best tested purity |
|---|---|
| Polaris Peptides | 99.8% |
| Guruite Biotechnology Co-Greatpeptide | 99.7% |
| Eros Peptides | 99.3% |
| Optima Chemical Supplies, Inc. | 99.2% |
Related peptides: Pemvidutide, Cotadutide.
Mazdutide activates both GLP-1 and glucagon receptors, while semaglutide activates only GLP-1 receptors. The glucagon component adds energy expenditure stimulation and hepatic fat reduction. This dual mechanism is shared with survodutide and cotadutide but distinguishes mazdutide from pure GLP-1 agonists.
No. As of 2025, mazdutide is only approved and available in China for weight management. It is not approved in the US, EU, UK, or other major markets. Innovent Biologics is the manufacturer.
They target different receptor combinations. Tirzepatide is a dual GLP-1/GIP agonist, while mazdutide is a dual GLP-1/glucagon agonist. Both aim to improve on pure GLP-1 agonism through a second receptor, but through different mechanisms — GIP enhances insulin secretion and may affect fat metabolism, while glucagon increases energy expenditure and hepatic fat oxidation.
Vendors with independent lab tests for it: Optima Chemical Supplies Inc.
Coverage on this site: Obesity Drugs Present Diverse Benefits, Harms, and Discontinuation Rates.